Back to top

Image: Bigstock

Why Earnings Season Could Be Great for Boise Cascade (BCC)

Read MoreHide Full Article

Investors are always looking for stocks that are poised to beat at earnings season Boise Cascade Company (BCC - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Boise Cascade is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for BCC in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 57 cents per share for BCC, compared to a broader Zacks Consensus Estimate of 45 cents per share. This suggests that analysts have very recently bumped up their estimates for BCC, giving the stock a Zacks Earnings ESP of +27.61% heading into earnings season.

Boise Cascade, L.L.C. Price and EPS Surprise

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that BCC has a Zacks Rank #1 (Strong Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Boise Cascade, and that a beat might be in the cards for the upcoming report.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Boise Cascade, L.L.C. (BCC) - free report >>

Published in